RayzeBio, Inc.
Clinical trials sponsored by RayzeBio, Inc., explained in plain language.
Biotech developing radiopharmaceutical therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New scan could reveal hidden kidney cancer Results expected Dec 2026 (estimated)
- New radioactive drug aims to fight gut tumors that resist standard therapy Results expected Dec 2026 (estimated)
- Radioactive drug takes aim at Hard-to-Treat tumors Results expected Feb 2027 (estimated)
- New imaging tracer could spot hidden cancers Results expected Jul 2027 (estimated)
- New combo therapy targets tough lung cancer in early trial Results expected Jul 2027 (estimated)
-
New imaging tracer could spot hidden cancers
Diagnosis Not yet recruitingThis early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…
Early phase 1 • Sponsor: RayzeBio, Inc. • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New scan could reveal hidden kidney cancer
Diagnosis Not yet recruitingThis early-phase study tests a new imaging agent called RYZ512 in 10 people with advanced clear cell kidney cancer that has spread. The agent is designed to attach to a protein (CAIX) found on these cancer cells, making them show up on scans. The goal is to see if it is safe and …
Early phase 1 • Sponsor: RayzeBio, Inc. • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC